Biotech | June 01, 2022
Novavax initiates phase 3 trial of its COVID-19 omicron booster
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
High level of vaccine efficacy maintained over a 6-month period of surveillance
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Subscribe To Our Newsletter & Stay Updated
